Bristol Myers Squibb's Sotyktu Shows Durable Efficacy in Psoriatic Arthritis Over Two Years — Bristol-Myers Squibb Company

Event summary

Bristol Myers Squibb presented two-year data from the Phase 3 POETYK PsA-2 study, showing durable efficacy and consistent safety for Sotyktu (deucravacitinib) in adults with active psoriatic arthritis.
ACR 20/50/70 response rates at Week 104 were 76.2%/52.6%/34.6% for continuous Sotyktu treatment and 76.9%/54.6%/37.7% for placebo-to-Sotyktu switchers.
Safety outcomes were consistent with previous reports, with no new safety signals identified through Week 104.
The data was presented at the Congress of Clinical Rheumatology - West (CCR-West) on September 17, 2026.

The big picture

Bristol Myers Squibb's long-term data for Sotyktu reinforces its potential as a durable oral treatment for psoriatic arthritis, a market with significant unmet needs. The consistent safety and efficacy profile observed over two years positions Sotyktu favorably against competitors and supports its expansion into other immune-mediated diseases. The company's focus on selective TYK2 inhibition aligns with broader industry trends towards targeted immunology therapies.

What we're watching

Market Positioning: Whether Sotyktu can sustain its efficacy and safety profile in long-term use to solidify its position in the psoriatic arthritis market.
Regulatory Approvals: The pace at which Bristol Myers Squibb can secure additional regulatory approvals for Sotyktu in other immune-mediated diseases.
Competitive Dynamics: How Sotyktu's performance compares to existing treatments like apremilast and other emerging therapies in the psoriatic arthritis space.